| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/13/2008 | EP1885695A2 Novel indoline compounds |
| 02/13/2008 | EP1885694A2 4-biarylyl-1-phenylazetidin-2-ones |
| 02/13/2008 | EP1885691A1 C5a receptor antagonists |
| 02/13/2008 | EP1885687A2 Tigecycline and methods of preparing 9-nitrominocycline |
| 02/13/2008 | EP1885686A2 Tigecycline and methods of preparing 9-aminominocycline |
| 02/13/2008 | EP1885684A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta-2 adrenergic receptor |
| 02/13/2008 | EP1885453A1 Substances having body mass redistribution properties |
| 02/13/2008 | EP1885392A2 Insulins combinations |
| 02/13/2008 | EP1885385A2 Phosphatidylinositol combination composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases |
| 02/13/2008 | EP1885379A2 Compounds and methods for treating seizure and paroxysmal disorders |
| 02/13/2008 | EP1885378A2 Organometal benzenephosphonate coupling agents |
| 02/13/2008 | EP1885377A2 Structured phospholipids for treating autoimmune and neurodegenerative diseases |
| 02/13/2008 | EP1885376A1 Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
| 02/13/2008 | EP1885375A1 Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety |
| 02/13/2008 | EP1885374A2 Pharmaceutical composition comprising an oleaginous ointment and vitamin d or the derivatives thereof in solubilised form |
| 02/13/2008 | EP1885373A2 Use of a clobetasol spray formulation for the treatment of psoriasis |
| 02/13/2008 | EP1885372A2 Uses of prostacyclin analogs |
| 02/13/2008 | EP1885371A1 Therapeutic compositions and methods |
| 02/13/2008 | EP1885370A2 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer |
| 02/13/2008 | EP1885369A2 Fused heterocyclic compounds, and compositions and uses thereof |
| 02/13/2008 | EP1885368A2 Novel dihydropyrimidine derivatives and their use as anti-cancer agents |
| 02/13/2008 | EP1885367A2 Method for the treatment of noise phobia in companion animals |
| 02/13/2008 | EP1885366A2 Pharmacological chaperones for treating obesity |
| 02/13/2008 | EP1885365A2 Treatment of sepsis and inflammation with alpha2a adrenergic antagonists |
| 02/13/2008 | EP1885364A1 Halogenated quindoline dimers for the treatment of cancer |
| 02/13/2008 | EP1885363A1 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease |
| 02/13/2008 | EP1885362A2 Novel chemical compounds |
| 02/13/2008 | EP1885361A2 Acyl hydrazones for treating cardiovascular diseases |
| 02/13/2008 | EP1885360A2 Inhibition of neuronal damage |
| 02/13/2008 | EP1885359A1 Fused imidazole derivatives and use thereof as aldosterone synthase inhibitors |
| 02/13/2008 | EP1885358A2 TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS |
| 02/13/2008 | EP1885357A1 Bicyclic 6-alkylidene-penems as class-d beta-lactamases inhibitors |
| 02/13/2008 | EP1885356A2 Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| 02/13/2008 | EP1885355A1 Anticancer combination therapy using sunitinib malate |
| 02/13/2008 | EP1885354A2 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis |
| 02/13/2008 | EP1885353A1 Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia |
| 02/13/2008 | EP1885352A2 Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| 02/13/2008 | EP1885351A1 Methods and compositions for the treatment of pain |
| 02/13/2008 | EP1885350A2 Formulations and methods for treating amyloidosis |
| 02/13/2008 | EP1885349A2 Sulphamides for treatment of cancer |
| 02/13/2008 | EP1885348A2 Antipyretic agents against vr1-antagonist-induced increases in body temperature |
| 02/13/2008 | EP1885347A2 Composition and method for treating nosebleeds |
| 02/13/2008 | EP1885346A1 Use of glycerol for improving cardiac function |
| 02/13/2008 | EP1885339A2 Formulations of a src/abl inhibitor |
| 02/13/2008 | EP1885336A2 Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders |
| 02/13/2008 | EP1885335A1 Surface-modified microparticles and methods of forming and using the same |
| 02/13/2008 | EP1885333A1 Pharmaceutical formulation of apomorphine for buccal administration |
| 02/13/2008 | EP1885328A1 Active ingredient combinations of glucosyl glycerides and creatine and/or creatinine |
| 02/13/2008 | EP1885187A2 Methods for treating drug resistant cancer |
| 02/13/2008 | EP1689748B1 Novel 8-(piperazine-1-yl)- and 8-( 1,4 diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug |
| 02/13/2008 | EP1689741B1 Benzoyl amino pyridyl carboxylic acid derivatives as glucokinase activators |
| 02/13/2008 | EP1689370B1 METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION COMPRISING 5-Chlor-N ( { (5-2-oxo-3- [4- (3-oxo-4-morpholinyl)-phenyl]-1, 3- oxazolidin-5-yl}-methyl)-2-thiophencarboxamide |
| 02/13/2008 | EP1678175B1 Medical use of zwitterionic compounds being cftr channel modulators |
| 02/13/2008 | EP1667960B1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 02/13/2008 | EP1663195B1 Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition |
| 02/13/2008 | EP1651227B1 Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof |
| 02/13/2008 | EP1648896B1 7-substituted 3-nitro-pyrazolo [1,5-a] pyrimidines |
| 02/13/2008 | EP1641793B1 Novel imidazopyridine compound ii with therapeutic effect |
| 02/13/2008 | EP1638951B1 Cyclohexyl sulphones as gamma-secretase inhibitors |
| 02/13/2008 | EP1631659A4 Modulation of the rna interference pathway |
| 02/13/2008 | EP1617827B1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances |
| 02/13/2008 | EP1613589B1 Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter |
| 02/13/2008 | EP1572152B1 Liposomal analgesic formulation comprising diclofenac and its use for treatment of horses |
| 02/13/2008 | EP1569664B1 Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
| 02/13/2008 | EP1553940B1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/13/2008 | EP1543821B1 External preparation |
| 02/13/2008 | EP1539138A4 Therapeutic process for the treatment of obesity and associated metabolic disorders |
| 02/13/2008 | EP1536796B1 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| 02/13/2008 | EP1517883B1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 02/13/2008 | EP1517679B1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 02/13/2008 | EP1513796B1 Phenyloxyalkanoic acid derivatives as hppar activators |
| 02/13/2008 | EP1513539B1 Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases |
| 02/13/2008 | EP1490025B1 Nanoparticulate compositions of map kinase inhibitors |
| 02/13/2008 | EP1480973B1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| 02/13/2008 | EP1478650A4 Novel boronate esters |
| 02/13/2008 | EP1470148A4 Double-stranded oligonucleotides |
| 02/13/2008 | EP1463716B1 Pyrrolidine and piperidine derivates as nk1 antagonists |
| 02/13/2008 | EP1455789A4 Imiquimod therapies |
| 02/13/2008 | EP1450814A4 Methods of inhibiting metastases |
| 02/13/2008 | EP1441701B1 Montelukast granule formulation |
| 02/13/2008 | EP1436010B1 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions, and methods |
| 02/13/2008 | EP1432677B1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same |
| 02/13/2008 | EP1427739A4 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum |
| 02/13/2008 | EP1424985B1 Use of derivatives of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity |
| 02/13/2008 | EP1423008B1 Highly crosslinked biocidal polystyrene hydantoin particles |
| 02/13/2008 | EP1414820B1 Non-nucleoside reverse transcriptase inhibitors |
| 02/13/2008 | EP1411923B1 Pharmaceutical compositions of amlodipine and atorvastatin |
| 02/13/2008 | EP1404650B1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments |
| 02/13/2008 | EP1401816B1 Process for the production of the piperidine derivative fexofenadine |
| 02/13/2008 | EP1373234B1 Urokinase inhibitors |
| 02/13/2008 | EP1353938B1 Androgenic 7-substituted 11-halogenated steroids |
| 02/13/2008 | EP1335908B1 Peroxisome proliferator activated receptor alpha agonists |
| 02/13/2008 | EP1335747B1 A composition of sodium channel blocking compound |
| 02/13/2008 | EP1313703B1 Prodrugs to nmda receptor ligands |
| 02/13/2008 | EP1303272B1 Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease |
| 02/13/2008 | EP1299420B1 Composition for pharmaceutical and cosmetic products |
| 02/13/2008 | EP1297843B1 Method of photoreduction of hemoglobin vesicles |
| 02/13/2008 | EP1289507B1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 02/13/2008 | EP1233770B1 Phosphonate compounds |
| 02/13/2008 | EP1168934B1 Hydrogel-forming system with hydrophobic and hydrophilic components |